Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKDC | P78527 | 3/20 | 0.43 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.36 |
| ▸ | GBA1 | P04062 | 1/20 | 0.36 |
| ▸ | HTR1A | P08908 | 5/20 | 0.34 |
| ▸ | HTR7 | P34969 | 4/20 | 0.34 |
| ▸ | ENPP1 | P22413 | 3/20 | 0.34 |
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.34 |
| ▸ | KIT | P10721 | 3/20 | 0.33 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.33 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3055184 | 0.88 | ENPP1 (0.39) | ENPP1KIT | |
| SCHEMBL3055920 | 0.86 | PRKDC (0.45) | PRKDCPDE3AGBA1HTR1AHTR7 | |
| SCHEMBL3060492 | 0.85 | PRKDC (0.41) | PRKDCPDE3AGBA1PDE10AKIT | |
| SCHEMBL3055462 | 0.85 | IGF1R (0.42) | PRKDCPDE3AGBA1HTR1AHTR7 | |
| SCHEMBL3042952 | 0.85 | PRKDC (0.42) | PRKDCPDE3AGBA1HTR1AHTR7 | |
| SCHEMBL3056948 | 0.81 | PDE3A (0.41) | PRKDCPDE3AGBA1HTR1AHTR7 | |
| SCHEMBL3060684 | 0.80 | PDE3A (0.43) | PRKDCPDE3AHTR1AHTR7PDE10A | |
| SCHEMBL3056861 | 0.79 | KIT (0.40) | PRKDCPDE3AHTR1APDE10AKIT | |
| SCHEMBL3062070 | 0.78 | PIM1 (0.45) | PRKDCPDE3AHTR1AHTR7ENPP1 | |
| SCHEMBL3057198 | 0.78 | CHRNB1 (0.42) | PRKDCPDE3APDE10AKIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100222353-A1 | AMINOPHTHALAZINE DERIVATIVE COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2010-09-02 | — | — | US | claimed |
| EP-1981868-A2 | AMINOPHTHALAZINE DERIVATIVE COMPOUNDS | Pfizer Products Inc. (US) | 2008-10-22 | — | — | EP | claimed |
| WO-2007085954-A2 | AMINOPHTHALAZINE DERIVATIVE COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2007-08-02 | — | — | WO | claimed |
| US-20100222353-A1 | AMINOPHTHALAZINE DERIVATIVE COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2010-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222353-A1 | AMINOPHTHALAZINE DERIVATIVE COMPOUNDS | PDE12, PDE5A, PDE2A | PRKDC 1357/4885PDE3A 5/4885GBA1 317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.